Skip to main content

Xembify Side Effects

Generic name: immune globulin subcutaneous

Medically reviewed by Last updated on Feb 14, 2024.

Note: This document contains side effect information about immune globulin subcutaneous. Some dosage forms listed on this page may not apply to the brand name Xembify.

Applies to immune globulin subcutaneous: subcutaneous solution.


Subcutaneous route (Solution)

Warning: ThrombosisThrombosis may occur with immune globulin products, including immune globulin-hipp. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.For patients at risk of thrombosis, administer immune globulin-hipp at the minimum dose and infusion rates practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Serious side effects of Xembify

Along with its needed effects, immune globulin subcutaneous (the active ingredient contained in Xembify) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking immune globulin subcutaneous:

More common

Incidence not known

Other side effects of Xembify

Some side effects of immune globulin subcutaneous may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to immune globulin subcutaneous: subcutaneous solution.


The most common adverse events were local reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, and cough.[Ref]


Very common (10% or more): Local reactions (49%), infusion site erythema, injection site pain

Common (1% to 10%): Injection site swelling, injection site bruising

Uncommon (0.1% to 1%): Injection site edema

Postmarketing reports: Infusion site ulcer[Ref]

Nervous system

Very common (10% or more): Headache (29.2%)

Common (1% to 10%): Migraine, dizziness, somnolence

Uncommon (0.1% to 1%): Burning sensation

Postmarketing reports: Tremor, paresthesia[Ref]


Very common (10% or more): Diarrhea (18.8%), nausea (12.2%), vomiting, abdominal pain

Common (1% to 10%): Abdominal pain upper, abdominal discomfort, abdominal pain lower[Ref]


Very common (10% or more): Erythema (10.8%)

Common (1% to 10%): Rash, pruritus, urticaria[Ref]


Common (1% to 10%): Hypersensitivity

Postmarketing reports: Allergic-anaphylactic reactions (e.g. swollen face or tongue and pharyngeal edema, pyrexia, chills, dizziness, hypertension or changes in blood pressure, malaise)[Ref]


Common (1% to 10%): Hypotension

Rare (less than 0.1%): Hot flush

Postmarketing reports: Chest discomfort (including chest pain), tachycardia[Ref]


Very common (10% or more): Fatigue (12.5%)

Common (1% to 10%): Pain in extremity, pain, contusion, hematoma

Uncommon (0.1% to 1%): Anti-GAD antibody positive

Rare (less than 0.1%): Hematoma[Ref]


Very common (10% or more): Cough (10.4%)

Common (1% to 10%): Oropharyngeal pain

Rare (less than 0.1%): Nasopharyngitis

Postmarketing reports: Dyspnea, laryngospasm[Ref]


Very common (10% or more): Pain in extremity

Common (1% to 10%): Back pain, arthralgia, chills, myalgia[Ref]


Uncommon (0.1% to 1%): Coombs direct test positive[Ref]


1. (2006) "Product Information. Vivaglobin (immune globulin subcutaneous)." *ZLB Bioplasma Inc

2. (2018) "Product Information. Hizentra (immune globulin subcutaneous)." CSL Behring LLC

3. Cerner Multum, Inc. "UK Summary of Product Characteristics."

4. Cerner Multum, Inc. "Australian Product Information."

5. (2018) "Product Information. Cuvitru (immune globulin subcutaneous)." Baxter Healthcare Corporation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.